Drug Trial Radar · NCT04669171
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Jul 5, 2021
Primary completion
May 30, 2029
Study completion May 30, 2034
Sponsor
- Lead sponsor
- EnteromeIndustry
- Sponsor type
- Industry
- First posted
- Dec 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL
Conditions
- Follicular Lymphoma
- Marginal Zone Lymphoma
Interventions
EO2463Biological
Multiple dose of EO2463
lenalidomideDrug
D1-21 of 4-weekly cycles
rituximabBiological
Multiple doses of rituximab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Recommended Phase 2 Dose | Adverse Events Assessment |Time frame: Up to 24 months
- Phase 2: Overall Response RateTime frame: Up to 24 months
- Phase 2: Complete Response RateTime frame: Up to 24 months
Locations
11 sites in 4 countries. Site status is shown where the registry gives one.
Dana Farber Cancer Institute
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center)
Rochester, New York
University of Washington-Seattle Cancer Care Alliance
Seattle, Washington
CHU d'Amiens-Picardie - Hopital SUD
Amiens, France
IRCCS Policlinico San Matteo Foundation - University of Pavia
Naples, Italy
IRCCS Policlinico San Matteo Foundation - University of Pavia
Pavia, Italy
University Hospital Vall d'Hebron, Institute of Oncology
Barcelona, Spain
Clinica Universidad de Navarra
Madrid, Spain
Clinica Universidad de Navarra
Pamplona, Spain
Hospital Clinico Universitario de Salamanca
Salamanca, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.